Skip to main content
Delfa

← All assets

Lithium

6 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

6

Ongoing

0

Recruiting

0

Completed

5

Sites

17

Countries

3

Endpoints

74

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 74 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1/2
1
Phase 2
4
Phase 4
1

Trials by status

Completed
5
Unknown
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Behavior / neuropsychiatric
20
Other (unclassified)
19
Global cognition
6
Neuroimaging
6
Memory
4
Fluid / digital biomarkers
4
Caregiver / quality of life
4
Executive function / language
2
Function / daily living
2
Tau biomarkers
2
Safety / tolerability / PK
2
Other clinical outcomes
2
Amyloid biomarkers
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 16 of 74 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neuropsychiatric Inventory (NPI)Behavior

14

Mini-Mental State Examination (MMSE)Cognition

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

6 of 6

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT00703677A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration

Lithium

Frontotemporal dementia

Age 40-80Ph 1/2Completed9Jan 2010-results
NCT02129348Treatment of Psychosis and Agitation in Alzheimer's Disease

Lithium

Alzheimer’s disease

Alzheimer's diseasePh 2Completed4Jan 202025results
NCT01055392Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease

Lithium

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Age 60-80Ph 2Unknown1Mar 20093
LithiumLow-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia

Lithium

Frontotemporal dementia

MMSE 5-26Ph 2Completed1Nov 2022-results
LATTICELithium As a Treatment to Prevent Impairment of Cognition in Elders

Lithium

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Age ≥60Ph 4Completed1Aug 20242results
NCT00088387Effect of Lithium and Divalproex in Alzheimer's Disease

Divalproex, Lithium

Alzheimer’s disease

Alzheimer's diseasePh 2Completed1Mar 20053

Showing 1-6 of 6 trials